< 生产厂家价格 >

阿糖腺苷

阿糖腺苷用途

Vidarabine是核苷类抗生素,分离自链霉菌,能抗单纯性疱疹和水痘-带状疱疹病毒。

点击显示

阿糖腺苷名称

[ CAS 号 ]:
5536-17-4

[ 中文名 ]:
阿糖腺苷

[ 英文名 ]:
Vidarabine

[中文别名 ]:

[英文别名 ]:

Adenine, 9-β-D-arabinofuranosyl-
Vidarabine
adenine arabinoside
ara-adenosine
MFCD00065471
9-(β-D-Arabinofuranosyl)-9H-purin-6-amine
9H-Purin-6-amine, 9-β-D-arabinofuranosyl-
9-(b-D-Arabinofuranosyl)adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
ara-A

阿糖腺苷生物活性

[ 描述 ]:

Vidarabine是核苷类抗生素,分离自链霉菌,能抗单纯性疱疹和水痘-带状疱疹病毒。

[ 相关类别 ]:

信号通路 >> 抗感染 >> HSV

信号通路 >> 细胞周期/DNA损伤 >> 核苷抗代谢药/类似物

研究领域 >> 感染

[参考文献]

[1]. Whitley, R., et al., Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs, 1980. 20(4): p. 267-82.

[相关活性小分子]

阿糖腺苷物理化学性质

[ 密度 ]:
2.1±0.1 g/cm3

[ 沸点 ]:
676.3±65.0 °C at 760 mmHg

[ 熔点 ]:
260-265ºC (dec.)

[ 分子式 ]:
C₁₀H₁₃N₅O₄

[ 分子量 ]:
267.241

[ 闪点 ]:
362.8±34.3 °C

[ 精确质量 ]:
267.096741

[ PSA ]:
139.54000

[ LogP ]:
-1.02

[ 外观性状 ]:
白色至灰白色结晶粉末

[ 蒸汽压 ]:
0.0±2.2 mmHg at 25°C

[ 折射率 ]:
1.907

[ 储存条件 ]:
库房通风低温干燥

阿糖腺苷MSDS

阿糖腺苷毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: AU6200000

CHEMICAL NAME :: Adenine, 9-beta-D-arabinofuranosyl-

CAS REGISTRY NUMBER :: 5536-17-4

LAST UPDATED :: 199701

DATA ITEMS CITED :: 48

MOLECULAR FORMULA :: C10-H13-N5-O4

MOLECULAR WEIGHT :: 267.28

WISWESSER LINE NOTATION :: T56 BN DN FN HNJ IZ D- ET5OTJ B1Q CQ DQ *D-ARABINO

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: Standard Draize test

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Rodent - rabbit

TYPE OF TEST :: Standard Draize test

ROUTE OF EXPOSURE :: Administration into the eye

SPECIES OBSERVED :: Rodent - rabbit

TYPE OF TEST :: Standard Draize test

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Rodent - guinea pig

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 105 mg/kg/1W-I

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions Behavioral - tremor

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human

DOSE/DURATION :: 300 ug/kg

TOXIC EFFECTS :: Behavioral - anorexia (human) Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human

DOSE/DURATION :: 2 mg/kg

TOXIC EFFECTS :: Brain and Coverings - changes in surface EEG Behavioral - toxic psychosis Behavioral - ataxia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >5 gm/kg

TOXIC EFFECTS :: Liver - other changes

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1476 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 8914 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 302 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 7800 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 3057 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 5086 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 442 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 4200 mg/kg/28D-I

TOXIC EFFECTS :: Skin and Appendages - dermatitis, other (after systemic exposure) Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 61600 mg/kg/4W-I

TOXIC EFFECTS :: Behavioral - muscle weakness Liver - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 1400 mg/kg/28D-I

TOXIC EFFECTS :: Skin and Appendages - dermatitis, other (after systemic exposure)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Primate - monkey

DOSE/DURATION :: 2100 mg/kg/28D-I

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - visual field changes Behavioral - tremor Behavioral - muscle weakness

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 2 gm/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 2 gm/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 2500 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - body wall

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 2500 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravaginal

DOSE :: 1316 mg/kg

SEX/DURATION :: female 15-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Administration onto the skin

DOSE :: 2613 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Administration onto the skin

DOSE :: 2613 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Administration onto the skin

DOSE :: 260 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

DOSE :: 13 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :: Cytogenetic analysis

TEST SYSTEM :: Mammal - species unspecified Cells - not otherwise specified

DOSE/DURATION :: 1 mmol/L

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 120,139,1983 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5559 No. of Facilities: 26 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 1307 (estimated) No. of Female Employees: 664 (estimated)

点击显示

阿糖腺苷安全信息

[ 符号 ]:

GHS08

[ 信号词 ]:
Warning

[ 危害声明 ]:
H361

[ 警示性声明 ]:
P281

[ 危害码 (欧洲) ]:
Xn: Harmful;

[ 风险声明 (欧洲) ]:
R63

[ 安全声明 (欧洲) ]:
36/37-36-26

[ 危险品运输编码 ]:
UN 2811

[ WGK德国 ]:
3

[ RTECS号 ]:
AU6200000

[ 包装等级 ]:
II

[ 危险类别 ]:
6.1(a)

[ 海关编码 ]:
29349990

阿糖腺苷合成路线

阿糖腺苷上下游产品

阿糖腺苷上游产品

阿糖腺苷下游产品

阿糖腺苷制备

方法一、以5'-腺嘌呤核苷酸(5'-AMP)为原料
经选择性对甲苯磺酰化，水解脱磷，溴化，乙酰化得8-羟基-N，3', 5'-O-三乙基-2’-O-对甲苯磺酰基腺苷，在甲醇-氨中环化，再在甲醇-硫化氢中开环得8-巯基阿糖腺苷，经氢解脱硫即可得阿糖腺苷。
5'-腺嘌呤核苷酸[对甲苯磺酰氯]→2'-O-对甲苯磺酰基腺苷-5’-单磷酸酯[氨水，甲酰胺]→2’-O-对甲苯磺酰基腺苷酸[Br₂]→8-溴-2’-O-对甲苯磺酰基腺苷[乙酸，醋酐]→8-羟基-N, 3', 5'-O-三乙基-2'-O-对甲苯磺酰基腺苷[甲醇氨]→8, 2'-O-环化腺苷[甲醇-硫化氢]→8-巯基阿糖腺苷[兰尼镍]→阿糖腺苷
方法二、以尿苷为原料
先与三氯氧化磷和二甲基甲酰胺反应，然后在碱性(pH=9)条件下水解得到阿糖尿苷，经嘧啶核苷磷酸化酶水解，温度60℃，脱去尿嘧啶得到阿糖-1-磷酸，经嘌呤核苷磷酸化酶催化，与腺嘌呤在60℃缩合得阿糖腺苷。
尿苷[三氯氧化磷，二甲基甲酰胺]→[pH9]阿糖尿苷[嘧啶核苷磷酸化酶]→[60℃]阿糖-1-磷酸[嘌呤核苷磷酸化酶]→[60℃]阿糖腺苷。

点击显示

阿糖腺苷海关

[ 海关编码 ]: 29349990

阿糖腺苷文献

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

Chem. Res. Toxicol. 23 , 171-83, (2010)

Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental...

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

J. Sci. Ind. Res. 65(10) , 808, (2006)

Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ...

Developing structure-activity relationships for the prediction of hepatotoxicity.

Chem. Res. Toxicol. 23 , 1215-22, (2010)

Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals ...

更多文献

阿糖腺苷

阿糖腺苷用途

阿糖腺苷名称

阿糖腺苷生物活性

阿糖腺苷物理化学性质

阿糖腺苷MSDS

详细MSDS(安全技术说明书)

阿糖腺苷毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

阿糖腺苷安全信息

阿糖腺苷合成路线

详细合成路线

阿糖腺苷上下游产品

阿糖腺苷上游产品

阿糖腺苷下游产品

阿糖腺苷制备

阿糖腺苷海关

阿糖腺苷文献

相关化工产品/化学物质：

相关药品：

推荐生产厂家/供应商：

相关化合物